Related references
Note: Only part of the references are listed.Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?
Fabrizio Cantini et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab
Lieke Tweehuysen et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4 Six-Month Results From a Controlled Cohort Study
Lieke Tweehuysen et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
Hillel Cohen et al.
ADVANCES IN THERAPY (2017)
Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
Hendrik Schulze-Koops et al.
RHEUMATOLOGY (2017)
Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
Till Uhlig et al.
RHEUMATOLOGY (2017)
Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany
John Waller et al.
PATIENT PREFERENCE AND ADHERENCE (2017)
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Robert Moots et al.
CURRENT RHEUMATOLOGY REPORTS (2017)
Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect
Mourad F. Rezk et al.
RHEUMATOLOGY AND THERAPY (2017)
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
The changing landscape of biosimilars in rheumatology
Thomas Doerner et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials
Priyanka Vashisht et al.
ARTHRITIS CARE & RESEARCH (2016)
Patient attitudes and understanding about biosimilars: an international cross-sectional survey
Ira Jacobs et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
Filipe C. Araujo et al.
CURRENT RHEUMATOLOGY REPORTS (2016)
The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO
Else Helene Ibfelt et al.
CLINICAL EPIDEMIOLOGY (2016)
The nocebo effect of drugs
Sara Planes et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2016)
WHAT INTRINSIC AND EXTRINSIC FACTORS AFFECT THE DEVELOPEMENT OF ANTI-DRUG ANTIBODY TO INNOVATOR INFLIXIMAB AND ITS BIOSIMILAR CT-P13 IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
J. Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
Elena Nikiphorou et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Medicine's inconvenient truth: the placebo and nocebo effect
M. H. Arnold et al.
INTERNAL MEDICINE JOURNAL (2014)
ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2013)
The Danish National Patient Register
Elsebeth Lynge et al.
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2011)
European biologicals registers: methodology, selected results and perspectives
A. Zink et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Share Paper
